1 Min Read
Nov 27 (Reuters) - Abbott Laboratories : * Abbott’s Humira (adalimumab) approved in Europe for severe active pediatric
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.